drugset / Trial / NCT02768415
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The hypothesis of this study is to discover if the all-oral therapy with apatinib plus oral vinorelbine can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 425 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Vinorelbine | Small molecule | 80 mg/m2 | Oral |